Business Of Biotech

Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.

Feb 5, 2024

46:59

Episode guests

Carsten Rudolph

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Ethris is developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, as well as prophylactic vaccines for mucosal, multivalent, and mutation-agnostic use.

Dr. Rudolph discusses the challenges in the mRNA field, including regulatory considerations, cold-chain storage requirements, and the need for creative reimbursement models.

Deep dives

The Potential of COVID Vaccines and mRNA Paradigm

The podcast episode discusses the potential of entering the COVID vaccine market from a new vaccine paradigm. It highlights the driving forces of COVID, fatigue, and vaccine hesitancy behind the commercial acceptance of a new product.

Introduction

2min

Development of Inhalable mRNA for Gene Therapy

10min

Origins and Focus on Pulmonary Space

12min

The Explosion of the RNA Space and Its Potential for Treating Diseases

3min

Addressing Risks and Opportunities in Developing Pulmonary Drugs

4min

Efficacy and Regeneration of Cells

14min

Goals, Partnerships, and Fundraising at an Investor Conference

2min

We love to hear from our listeners. Send us a message.

Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iteration of a new technology is ever the best iteration of that technology. On this week's episode of the Business of Biotech, we welcome Carsten Rudolph, Ph.D., co-founder and CEO of a company that recognizes this room for improvement. Ethris is developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines. Dr. Rudolph explains the concept, the business case, and how he's navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

Business Of Biotech

Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

The Potential of COVID Vaccines and mRNA Paradigm

Dr. Karsten Rudoff's Background and Entry into mRNA Space

Advancements in Messenger RNA Technology

Challenges and Progress in the mRNA Field

Remember Everything You Learn from Podcasts